Shanghai Junshi Biosciences (HKG:1877, SHA:688180) unit TopAlliance Biosciences recently agreed to grant LEO Pharma the exclusive right to store, distribute, promote, market, and sell toripalimab in certain regions of Europe for 12 years, a Monday bourse filing said.
The carcinoma drug will be sold by LEO Pharma in all current and future member states of the European Union, the European Economic Area, Switzerland, and the United Kingdom under the contract.